



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



LRRC14 siRNA (m): sc-149053



BACKGROUND

Leucine-rich repeats (LRRs) are 20-29 amino acid motifs that mediate protein-protein interactions. The primary function of these motifs is to provide a versatile structural framework for the formation of these protein-protein interactions. LRRs are present in a variety of proteins with diverse structure and function, including innate immunity and nervous system development. Several human diseases are associated with mutations in genes encoding LRR-containing proteins. The leucine-rich repeat-containing protein 14 (LRRC14) is a 493 amino acid protein that contains six LRR repeats. The gene encoding LRRC14 maps to chromosome 8, which encodes approximately 800 genes. Translocation of portions of chromosome 8 with amplifications of the c-Myc gene are found in some leukemias and lymphomas, and typically associated with a poor prognosis. Chromosome 8 is also associated with trisomy 8, Pfeiffer syndrome, congenital hypothyroidism and Waardenburg syndrome.

REFERENCES

1. Kobe, B. and Kajava, A.V. 2001. The leucine-rich repeat as a protein recognition motif. *Curr. Opin. Struct. Biol.* 11: 725-732.
2. Selicorni, A., Guerrieri, S., Ratti, A. and Pizzuti, A. 2002. Cytogenetic mapping of a novel locus for type II Waardenburg syndrome. *Hum. Genet.* 110: 64-67.
3. Matsushima, N., Tachi, N., Kuroki, Y., Enkhbayar, P., Osaki, M., Kamiya, M. and Kretsinger, R.H. 2005. Structural analysis of leucine-rich-repeat variants in proteins associated with human diseases. *Cell. Mol. Life Sci.* 62: 2771-2791.
4. Chen, Y., Aulia, S., Li, L. and Tang, B.L. 2006. AMIGO and friends: an emerging family of brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs. *Brain Res Rev.* 51(2): 265-274.
5. Mossafa, H., Damotte, D., Jenabian, A., Delarue, R., Vincenneau, A., Amouroux, I., Jeandel, R., Khouri, E., Martelli, J.M., Samson, T., Tapia, S., Flandrin, G. and Troussard, X. 2006. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. *Leuk. Lymphoma* 47: 1885-1893.
6. Agrelo, R., Cheng, W.H., Setien, F., Ropero, S., Espada, J., Fraga, M.F., Herranz, M., Paz, M.F., Sanchez-Cespedes, M., Artiga, M.J., Guerrero, D., Castells, A., von Kobbe, C., Bohr, V.A. and Esteller, M. 2006. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. *Proc. Natl. Acad. Sci. USA* 103: 8822-8827.
7. Dolan, J., Walshe, K., Alsbury, S., Hokamp, K., O'Keeffe, S., Okafuji, T., Miller, S.F., Tear, G. and Mitchell, K.J. 2007. The extracellular leucine-rich repeat superfamily; a comparative survey and analysis of evolutionary relationships and expression patterns. *BMC Genomics* 8: 320.
8. Ko, J. and Kim, E. 2007. Leucine-rich repeat proteins of synapses. *J. Neurosci. Res.* 85: 2824-2832.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Lrrc14 (mouse) mapping to 15 D3.

PRODUCT

LRRC14 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see LRRC14 shRNA Plasmid (m): sc-149053-SH and LRRC14 shRNA (m) Lentiviral Particles: sc-149053-V as alternate gene silencing products.

For independent verification of LRRC14 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149053A, sc-149053B and sc-149053C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

LRRC14 siRNA (m) is recommended for the inhibition of LRRC14 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor LRRC14 gene expression knockdown using RT-PCR Primer: LRRC14 (m)-PR: sc-149053-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.